$2.8M Zolgensma spinal muscular atrophy treatment approved by Health Canada

Health Canada has approved Zolgensma, a $2.8 million life-saving gene therapy for toddlers that replaces the dysfunctional gene which causes spinal muscular atrophy Type 1. As Morgan Black explains on the noon news, it’s exciting news for several Alberta families.